Introduction. Simian parvovirus (SPV) causes severe anemia in immunocompromised macaques. The closely related erythrovirus, parvovirus B19, causes anemia in susceptible humans and can be grown in human bone marrow mononuclear cells in vitro. We hypothesized that SPV may infect humans and replicate in human bone marrow mononuclear cells.
with the left ORF encoding the nonstructural proteins and the right ORF encoding the 2 capsid proteins, VP1 and VP2; and SPV DNA has 50% overall homology with parvovirus B19 DNA, and its proteins have 70% overall homology with B19 capsid proteins and 50% overall homology with B19 nonstructural protein [4] .
Because of the many similarities between B19 and SPV, we speculated that macaque handlers might be at risk of infection with SPV. We first tested serum samples from handlers, for cross-reacting antibody to SPV, and we also expressed SPV VP2 in Escherichia coli and used the partially purified fusion protein in a Western blot assay, to determine the prevalence of IgG antibodies to SPV VP2 in a cohort of macaque handlers, compared with that in healthy blood donors. We also tested SPV for its ability to infect human and macaque bone marrow mononuclear cells in vitro and to determine whether SPV uses the same cellular receptor for binding to permissive cells.
SUBJECTS, MATERIALS, AND METHODS
Serum samples for antibody testing. Serum samples were collected from 90 individuals (65 of whom had contact with macaques) after informed consent had been obtained (the protocol was approved by the Wake Forest University Institutional Research Board), were divided into groups by different degrees of exposure to macaques on the basis of the individuals' job responsibilities, and were anonymized. In addition, we tested serum samples from 100 healthy blood donors obtained as part of the National Heart, Lung, and Blood Institute (NHLBI) Retrovirus Epidemiology Blood Donor Study, NHLBI repository.
Detection of parvovirus antibodies by ELISA. Crossreacting antibodies to erythroviruses were tested by a commercial assay in which parvovirus B19 VP2 capsids served as antigen (Parvovirus B19 IgG Enzyme Immunoassay; Biotrin). All samples were tested in accordance with the manufacturer's protocol.
Detection of SPV antibody by Western blot. Serum samples were specifically tested for antibody to SPV by use of the viral VP2 expressed as a modified thioredoxin fusion protein.
Sequence coding for SPV VP2 was amplified by polymerase chain reaction (PCR), by use of cloned SPV DNA as template [4] , a sense primer (5 -acc-cgc-tcg-agg-cct-ctg-tca-cgt-cta-c-3 ) into which an XhoI restriction site was inserted (underlined), and an anti-sense primer (5 -acg-taa-ttc-tag-aag-agg-gtg-tactcg-ctt-tt-3 ) with an Xba1 restriction site. The amplified 1688-bp fragment (nt 3141-4828) of the VP2 gene was digested with restriction enzymes Xho1 and Xba1 and ligated into the expression vector pThioHis A (His-Patch ThioFusion Expression System; Invitrogen) cut at the same restriction-enzyme sites. The resultant plasmid was used to transform E. coli (DH5a-competent cells; Life Technologies). The fusion proteins were expressed in accordance with the manufacturer's protocol and were extracted from induced bacteria by use of Bacterial Protein Extraction Reagent (Pierce). As a control, His patch (HP)-thioredoxin (molecular weight, ∼15 kDa) was also expressed, by use of the HP-thioredoxin plasmid provided in the expression kit. The fusion proteins were partially purified by continuous-elution electrophoresis (Model 491 Prep Cell; Bio-Rad) on an 8%-polyacrylamide separating gel. In addition, nontransfected DH5a bacteria were processed in parallel, and equivalent fractions were used as a negative control to test serum samples.
Antibodies against SPV VP2 in serum samples were detected by immunoblot assay. The partially purified fusion proteins were separated by SDS-PAGE electrophoresis and transferred to nitrocellulose membranes, and nonspecific binding was blocked by incubating the membranes with blocking buffer (5% nonfat dry milk and 0.05% Tween 20 [Sigma] in PBS) for 1 h at room temperature or overnight at 4ЊC. The membrane was cut into strips and incubated with the serum samples (1:200 dilution in blocking buffer) for 1 h at room temperature. The membrane was washed 3 times and incubated with horseradish peroxidase-conjugated goat anti-human IgG (1:2500-1: 10,000; BioSource International) at room temperature before further washing and detection of immunoreactivity by chemiluminescence (ECL; Pierce) or enhanced CN/DAB substrate (Pierce). The presence of the 75-kDa band in the SPV-sample lane and its absence in the negative-control lane defined a positive reaction. All samples from handlers were also tested for reaction to the tag protein, HP-thioredoxin, to exclude a possible false-positive result caused by the fusion tag.
Expression of SPV VP2 capsids. SPV VP2 was expressed in insect cells by use of a recombinant baculovirus produced by the Bac-to-Bac system (Invitrogen). The SPV VP2 region was amplified by PCR with primers containing either an additional BamHI (SPV 5 primer) or XbaI (3 primer) site and cloned into pFastBac1, and recombinant bacmids and baculovirus were produced in accordance with the manufacturer's protocol. Sf9 cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained in Grace's medium with 10% fetal calf serum (FCS) and antibiotics. Sf9 cells were infected with recombinant baculovirus and harvested on day 4 or 7 after infection by tapping the cells into suspension and collecting them by centrifugation. The cells were lysed by freeze-thawing or incubation in 25 mmol/L hypotonic sodiumbicarbonate solution and Dounce homogenization. After centrifugation, viruslike particles (VLPs) were precipitated from the solution by 20% ammonium-sulfate precipitation and dialyzed against PBS, to remove the ammonium chloride, before cesium-chloride purification.
Hemagglutination (HA)/HA-inhibition (HAI) assays. HA and HAI assays were performed by use of dextrose-gelatinalbumin buffer (pH 5.8) and human erythrocytes, as described elsewhere for parvovirus B19 [5, 6] . B19 VP2 VLPs (MedImmune) were used as a control.
Bone marrow and cell culture. Bone marrow mononuclear cells were obtained from human volunteers, after informed consent had been obtained (protocol approved by NHLBI Institutional Review Board), by aspiration into preservative-free heparin. Bone marrow mononuclear cells were obtained from cynomolgus and rhesus macaques either by aspiration into preservative-free heparin (protocol approved by NHLBI Animal Care and Use Committee) or from the lower limbs at postmortem. Mononuclear cells were collected from the interface of the different phases after centrifugation over ficoll-hypaque (Lymphocyte Separation Medium; Organon Teknika) and were washed in Iscove's modified Dulbecco's medium (IMDM) with 20% FCS before use.
KU812Ep6 cells [7] were maintained in RPMI 1640 medium with 10% FCS and 6 U/mL erythropoietin. UT7/Epo-S1 cells [8] , a subclone of the UT7/Epo cell line previously shown to be permissive for parvovirus B19 [9] , were maintained in IMDM with 10% FCS and 2 U/mL erythropoietin.
SPV-containing serum was obtained from viremic cynomolgus macaques infected either as part of an outbreak [1] or experimentally [10] . The serum samples were estimated to con-tain and genome copies/mL of SPV by dot-blot 8 7 2 ϫ 10 2 ϫ 10 hybridization [1] .
Methylcellulose colony culture. The production of a viral cytotoxic effect on bone marrow mononuclear cells was assayed by use of a methylcellulose hematopoietic colony-inhibition assay, in a manner analogous to that used in the human bone marrow erythroid progenitor cell (colony forming unit-erythroid [CFU-E]) colony-inhibition assay for B19 [11] . Bone marrow mononuclear cells were counted and diluted to a density of cells/mL. SPV-containing serum samples (30 mL) 6 2 ϫ 10 or B19-containing serum samples, as a control, were added to 150 mL of the cell suspension and incubated for 1 h at 4ЊC. The mixture was then added to IMDM-0.9% methylcellulose medium with 10 U/mL erythropoietin and 100 U/mL interleukin (IL)-3, plated, and incubated at 37ЊC in 95% humidity and 5% CO 2 . Colony formation was assayed by microscopic examination at days 7 (for late erythroid progenitor cells [CFU-E-derived colonies]) and 10 (for early erythroid progenitor cells [burst-forming unit-erythroid {BFU-E}-derived colonies and granulocyte/myeloid {GM} progenitor CFU-GM-derived colonies]). For virus neutralization, virus-containing serum samples (30 mL) were preincubated with 20 mL of antibody for 2 h at 4ЊC, before being added to the cell-suspension mixture, incubated for a further 1 h, and plated as above.
SPV-infection studies. For infection, 1-5 mL of virus-containing serum [1] was added to 1 mL of bone marrow mononuclear cells (10 6 cells/mL) in IMDM with 20% FCS, 5-10 U/ mL erythropoietin, and 100 U/mL IL-3 and was cultured at 37ЊC. For RNA, DNA, and protein studies, cells were harvested at various times after inoculation.
DNA studies. The amount of SPV DNA present in serum samples was measured by dot-blot hybridization and PCR. Infected bone marrow mononuclear cells were harvested at 2 and 48 h after inoculation and washed in PBS to remove nonadherent virus. Total DNA was purified by phenol-chloroform extraction after SDS-proteinase K cell lysis [12] or by use of the Qiamp DNA extraction kit (Qiagen). Total extracted DNA was quantitated by absorbance reading. Ten-fold dilutions of normalized amounts of purified DNA were immobilized onto a nylon membrane (Hybond N+; Amersham) by filtration, by use of a dot-blot apparatus (Bio-Dot; Bio-Rad). Viral DNA was hybridized with either a 32 P-labeled or a digoxygenin-labeled (DIG DNA labeling kit; Boehringer Mannheim) pYT103 insert probe, an almost full-length clone of parvovirus B19 DNA cross-hybridizing to SPV DNA [1] . Digoxygenin-labeled hybridized probes were then detected by antidigoxygenin alkaline phosphatase-conjugated Fab fragments and Lumi-Phos 530 (Boehringer Mannheim) chemiluminescent detection.
To confirm the results of dot-blot hybridization, PCR was performed on cells collected 2 h, 2 days, and 4 days after infection. Amplification was performed (30 cycles) by use of the primers SPV-F (nt 230-249) and SPV-SR (nt 2568-2549). Products were confirmed by Southern blot, by use of a 32 P endlabeled oligonucleotide probe (SPV-SP [nt 2474-2493]).
Southern-blot analysis of purified DNA was performed to detect replicative forms of SPV DNA. Purified DNA was cleaved with restriction endonuclease BamHI (no cuts in SPV genome) [4] or HindIII (1 cut in SPV genome), and the fragments were separated by electrophoresis in a 1% agarose gel and transferred to a nylon membrane (Nytran; Schleicher and Schuell) by alkaline downward blotting [13] . SPV DNA was then probed and detected as described above.
RNA studies. For RNA studies, 1-3 mL of SPV-containing serum [1] was added to either 1 mL of bone marrow mononuclear cells (10 6 cells/mL) in IMDM with 20% fetal calf serum, 10 U/mL erythropoietin, and 100 U/mL IL-3 or cell lines in their appropriate media and were allowed to bind for 2 h. After this time, the cells were centrifuged to remove nonadherent virus, and an aliquot was stored. The rest of the cells were resuspended in tissue-culture medium and placed in culture at 37ЊC. Cells were harvested at different time points after inoculation, washed in PBS to remove nonadherent virus, and stored frozen until tested.
RNA was extracted from the cells by RNA STAT-60 (Tel test). To exclude DNA contamination in the assays performed to detect nonspliced transcripts, RNA (1 mg) was predigested with DNase I (2 U for 15 min at room temperature, followed by 10 min at 65ЊC to inactivate the DNase I; Promega) before cDNA synthesis by use of 50 pmol of random hexamers in a 25-mL reverse transcriptase (RT) mixture, in accordance with the RNA PCR Core kit protocol (Perkin-Elmer). RT was inactivated by heating the samples for 5 min at 99ЊC, before seminested PCR. Amplification was performed To confirm the presence of RNA, b-actin was amplified as an internal control, as described elsewhere [14] .
RESULTS

Detection of cross-reacting antibodies.
We hypothesized that SPV antibodies would be cross-reactive with B19 antigens, and, therefore, all samples were tested by commercial ELISA with recombinant B19 VP2 as antigen. From the 2 groups of handlers exposed or not exposed to macaques, 60% and 71% of samples, respectively, tested positive, which are similar to the prevalence rate of B19 in the population of healthy blood donors (75%) (table 1) . Initial attempts to express SPV VP2 in insect cells were unsuccessful, and, therefore, we expressed these proteins in bacterial cells. Of the 90 serum samples from handlers, 1 sample reacted with HP-thioredoxin control and was excluded from the analysis. Of the other 89 samples, 51% from exposed handlers and 37% from nonexposed handlers had detectable antibodies. Of the samples from the healthy blood donors, 34% had antibody that reacted with SPV. There was a direct correlation with the amount of exposure to macaques (table 1) .
If only the samples that tested seronegative in the ELISA were considered, 11 of 26 samples from exposed handlers, compared with 7 of 31 samples from nonexposed handlers, had antibodies to SPV ( ). P p .1 Binding of SPV VLPs to globoside. When Sf9 cells were infected with recombinant baculovirus expressing SPV VP2, VLPs were produced. Examination by electron microscopy revealed almost pure preparations of VLPs, with typical icosahedral structure and a diameter of ∼25 nm, that were virtually indistinguishable from B19 preparations (figure 1). Analysis using cesium-chloride density gradients confirmed that the particles had a density of 1.2 g/cm 3 (refractive index, 1.356). SPV VP2 capsids hemagglutinated human cells. The HA was blocked by globoside and Forsmann antigen to high titer but not by other glycosphingolipids (table 2), suggesting that SPV, like B19, used globoside as its receptor.
Previous testing of human serum samples for B19 HAI activity demonstrated the presence of an inhibitor in human serum samples [6] ; therefore, human serum samples were not tested for SPV HAI. Instead, anti-B19 monoclonal antibodies (MAbs) were tested for their ability to block HA of human cells. Both MAb E and 521-5D, which have previously been shown to block B19 HA [6] , had no HAI activity against SPV (HAI titer !100). A rabbit polyclonal serum sample raised against SPV VP2 capsids had no significant HAI activity against B19 or SPV (B19 HAI titer, 100; SPV HAI titer, !100).
Colony assays. The production of a viral cytotoxic effect on macaque bone marrow mononuclear cells was assayed by use of a hematopoietic colony-inhibition assay, in a manner analogous to that used for the human bone marrow CFU-E colony-inhibition assay for B19 [11] . As with parvovirus B19, there was inhibition of macaque CFU-E and BFU-E erythroid colony formation but not of CFU-GM myeloid colony formation (data not shown). This inhibition was dose related and was specifically blocked by rabbit polyclonal anti-SPV antibodies.
There was a similar inhibition of human erythroid progenitor cells (figure 2). Although they did not block HA, both MAb E and 521-5D partially blocked the SPV inhibition of human BFU-E (figure 2). Serum samples from 2 healthy blood donors that were positive for B19 antibody but negative for SPV reactivity were also tested. Both samples had B19 neutralizing ac- Ceramide trihexoside Gal-Gal-Glc-Cer
Globoside GalNAc-Gal-Gal-Glc-Cer 400 800 Forssman GalNAc-GalNAc-Gal-Gal-Glc-Cer 400 800 Asialoganglioside GM2 GalNAc-Gal-Glc-Cer !10 !10 NOTE. Purified glycosphingolipids (Sigma) were dissolved in saline (0.5 mg/mL) and tested in duplicate by doubling dilution in the HAI assay. The end point was the dilution that inhibited 50% agglutination of simian parvovirus or B19 capsids (20 mg/mL). Results of a typical experiment are shown; those for SPV and B19 are titers. DNA studies. A significant increase in the amount of SPV DNA present 48 h after infection was observed in macaque bone marrow mononuclear cells. A smaller but definite increase in SPV DNA was also present in human bone marrow mononuclear cells ( figure 3A and 3B ), observed by use of both dot blot and PCR. Southern-blot analysis of purified DNA was performed to detect replicative forms of SPV DNA. Purified DNA was cleaved with restriction endonuclease BamHI (no cuts in SPV genome) [4] or HindIII (1 cut in SPV genome). Viral ssDNA and dsDNA forms were present in SPV-infected macaque bone marrow mononuclear cells as well as in human bone marrow mononuclear cells (data not shown).
RNA and protein studies. RNA was extracted from infected bone marrow mononuclear cells and tested for both nonstructural protein and capsid protein RNA transcripts. After treatment with DNase I, an 810-bp product was observed in the macaque bone marrow cultures only after reverse transcription, indicating that this was not due to the SPV DNA used in the infection (figure 4). Similar bands were seen in the bone marrow cultures from both rhesus macaques and humans and in KU812Ep6 and UT7/Epo-S1 cells. By use of the primers based in the capsid region of the viral genome, a single PCR product of 867 bp was observed in all the bone marrow cultures and in KU812Ep6 and UT7/Epo-S1 cells. This product was cloned and sequenced, to confirm its identity and to characterize the splice junction in SPV. Sequencing showed that, in both the human and the macaque cultures, the major splice junction was between nt 279 and 1792. Additional splice junctions between nt 279 and 1740 and nt 333 and 1792, as observed in SPV fetal infection [15] , were also observed in SPV infection of human bone marrow mononuclear cells.
DISCUSSION
SPV was originally identified in cynomolgus macaques who developed life-threatening anemia. Light microscopic examination of bone marrow mononuclear cells demonstrated intranuclear inclusion bodies within erythroid cells that were characteristic of parvovirus infection, and electron microscopic examination revealed parvovirus particles within the intranuclear inclusions [1] . Cloning and sequencing confirmed that this was a novel parvovirus, with closest similarity to the human erythrovirus, parvovirus B19 [4] . Experimental inoculation of SPV into naive macaques induces temporary arrest of erythroid cell production, analogous to that observed in B19 infection in humans [10] . Similarly, inoculation of SPV into cynomolgus macaque fetuses during the midtrimester and before the onset of immunocompetence leads to the production of fetal hydrops [3] (M.G.O., J. C. Veille, W. A. Block, A. R. Turner, N. S. Young, and K.E.B., unpublished data). These observations suggest that SPV infection of host cells is very similar to B19 infection of host cells, further suggesting that SPV could be a useful animal model for studies of B19 infection.
With the finding of clinical similarity between SPV and B19 infection and with the increased awareness of animal zoonoses, we queried whether there was any evidence of humans being infected with SPV. There was no clinical evidence of a B19-like illness in handlers exposed to macaques at the time of the SPV outbreak. Although there was no correlation when a B19-based ELISA was used for detection, there was a clear correlation between exposure to macaques and the presence of SPV antibody. Previous studies comparing the antibody response to conformational and linear epitopes of B19, detected by ELISA and Western blot, respectively, showed that the conformational responses lasted much longer [16] . In our own unpublished studies, testing rhesus macaques indicated that, although 26 of 48 macaques had antibody to linear SPV antigens detected by Western blot, none of the macaques had antibodies detected by B19-based ELISA (2 macaques received equivocal results), suggesting that the B19-based ELISA does not readily detect SPV antibody responses. However, clearly, there is some crossreactivity between SPV and B19 antigens, as both B19-positive serum samples from donors with presumably no exposure to macaques and MAb to B19 inhibited SPV toxicity in the methylcellulose assays.
Detection of SPV antibodies in the presence of serum found to be negative by B19-based ELISA does not provide definitive evidence that the SPV-reactive antibody reflects exposure to SPV, because of possible cross-reactivity. We therefore directly tested SPV for its ability to infect human bone marrow mononuclear cells in vitro. We have demonstrated that SPV VP2 capsid protein, like B19 VP2 protein, self-assembled to produce viruslike capsids [17] and that both bound to the B19 receptor, globoside, or blood group P antigen [5] . SPV infected macaque erythroid progenitor cells in vitro and produced erythroid colony inhibition in a manner highly analogous to that of human parvovirus B19 infection and cytotoxicity on human erythroid progenitor cells. In addition, it appears that SPV can infect, although at lower efficiency, human bone marrow mononuclear cells.
We have also previously shown that parvovirus B19 can infect macaque bone marrow mononuclear cells [18] . Sequence homology also suggests that these viruses are closely related evolutionarily. Perhaps, human parvovirus B19 evolved from SPV in a manner analogous to that of the human and simian retroviruses. Certainly, the major viral replication and expression characteristics, plus dependence on host intracellular factors, have been evolutionarily conserved between parvovirus B19 and SPV. However, the viruses are not identical. Although the structural proteins and nonstructural protein are conserved between SPV and B19, this does not appear to be the case for the 2 smaller (7.5 and 11 kDa) proteins present in the B19 genome [19, 20] . Although there is an analogous ORF for the 11-kDa protein in SPV, the putative protein would not contain the SH3-binding domain observed in B19 [21] , and there does not appear to be an SPV protein analogous to the 7.5-kDa protein in B19. Similarly, by comparison with the transcription map of parvovirus B19, we would have expected to observe 2 spliced transcript products by use of our capsid RT-PCR. However, in the present study, using bone marrow or megakaryoblastoid cell lines, we observed only a "single" product, with the splice junction predominantly between nt 279 and 1792. Additional splice junctions were obtained, as also seen in studies of transcripts in SPV-infected fetal liver [15] , and studies are in progress to obtain the full transcription map of SPV and to determine whether the virus encodes similar small viral proteins [22] .
The original outbreak of SPV was not an isolated event; similar mass infections have been documented in other macaque colonies [23] (authors' unpublished data), and the results of our serological studies suggest that ∼50% of macaques have antibodies to SPV or related viruses. Seroprevalence increases with age in captive monkeys [24] , suggesting that these viruses do circulate in monkey colonies in the United States. We have identified rhesus parvovirus and pig-tailed macaque parvoviruses in monkey colonies [25] [26] [27] , and some of the earlier reports of the hematological abnormalities seen with simian AIDS may well represent unrecognized parvovirus infection [28] [29] [30] . Thus, this is not an unusual infection, and workers handling macaques need to be aware of it.
Recently, variants of B19 have been described in human serum [31, 32] , bone marrow [33] , liver [34] , and skin [35] . Although these sequences differ significantly from the classic B19 sequence at the DNA level (∼10%), at the amino acid level, the proteins are all highly conserved, including the minor 7.5-and 11-kDa proteins that are missing or significantly different in the SPV genome. There is no evidence to suggest that these newly described genotypes are a result of recent introduction from nonhuman primates. However, the DNA sequences are sufficiently different-that is, standard PCR primers designed against only B19 genotype 1 sequences would miss these new genotypes [32] . Similarly, although high-titer SPV can be detected by direct hybridization assays with B19-specific probes, B19-specific PCR would not detect SPV infection or whether suspected specific primers should be employed.
In summary, our data show a correlation between exposure to macaques and the presence of SPV antibody. Although it has not been established that humans can be infected with SPV, given the ability of the virus to replicate in human bone marrow and cell lines in vitro and the high levels of viremia that develop in infected macaques, this putative zoonosis should not be ignored. Although we would predict that most SPV infections in humans would be mild and that individuals with B19 antibodies would likely be protected, immunosuppressed handlers (HIV infected, for example) may be at risk of infection, pregnant handlers may be at risk of fetal infection, and infection could potentially be transmitted to others through blood transfusions from a viremic handler or to immunosuppressed contacts, with more-serious consequences. B19 has already been documented to be transmitted with kidney and other organ transplants [36] [37] [38] , and SPV or related parvoviruses are a potential infection in nonhuman primate-to-human xenotransplantation. With the current concern of animal viruses infecting humans, more studies are required to ascertain the risk of animal handlers becoming infected with nonhuman primate parvoviruses.
